发展历程
| 2025 |
SM-1治疗复发高级别脑胶质瘤I期临床结果亮相2025年ESMO年会并获口头汇报； SM-1治疗复发高级别脑胶质瘤I期临床数据亮相第十届创新与投资大会； SM-1联合替莫唑胺治疗复发高级别脑胶质瘤的I期临床结果在Neoplasia杂志正式发表； SM-1联合卡培他滨在晚期结直肠癌中临床研究获得临床试验许可； SM-1联合他莫昔芬治疗激素受体阳性（HR+）/人类表皮因子受体2阴性（HER2-）晚期乳腺癌获得临床试验许可。 |
||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2024 |
SM-1联合替莫唑胺治疗复发高级别脑胶质瘤II期临床研究启动； SM-1联合替莫唑胺治疗初治高级别脑胶质瘤II期临床研究获得临床试验许可; 真兴医药荣获“2024年深圳市专精特新中小企业”称号。 |
||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2023 |
“真兴医药”被评选为第五届粤港湾大湾区生物科技创新企业50强；
SM-1项目II期临床试验在山东大学第二医院正式启动； SM-1联合替莫唑胺治疗高级别脑胶质瘤I期研究数据在＂第八届中国医药创新与投资大会＂临床数据首发专场中披露。 |
||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2022 |
SM-1开展Ⅱ期临床研究；
SM-1联合放疗治疗头颈部肿瘤I期临床研究获批。 |
||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2021 |
SM-1联合替莫唑胺治疗高级别脑胶质瘤I期临床研究获批；ZXS-001项目启动预实验研究； ZXS-001项目启动预实验研究。 |
||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2020 |
SM-1项目获得伦理批件，正式启动临床研究； 真兴医药完成首轮融资； ZXBT-1158项目获得临床试验许可。 |
||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2019 |
SM-1项目获得临床试验许可； ZXBT-1158项目完成临床前研究。 |
||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2018 |
SM-1项目提交临床试验申请； ZXBT-1158项目发明专利授权； |
||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2016 | ZXBT-1158项目立项 | ||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2014 |
深圳市真兴医药技术有限公司成立； SM-1项目获深圳市科创委“协同创新计划”立项； SM-1项目启动临床前研究； |
||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2013 | 深圳市真兴贝特医药技术有限公司成立 | ||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2012 | SM-1项目获国家“十二五”“重大新药创制”科技重大专项课题立项 | ||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2010 | SM-1首项发明专利授权 | ||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2009 | 筛选出新型靶向小分子化合物SM-1 | ||||||||
| 一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一一 | |||||||||
| 2007 | 成立深圳市湘雅生物医药研究院，从事新型靶向小分子抗肿瘤药物研发，致力于开发拥有自主知识产权的原创药物。 | ||||||||
